The treatment of atopic dermatitis in canine patients has been completely transformed by the introduction of oclacitinib, which was approved in 2014. Oclacitinib, which is a powerful Janus kinase inhibitor, is a novel targeted approach that suppresses the itching-inducing pathways that are the root cause of inflammatory skin conditions in dogs. Additionally, the development and production of...